{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+NOS&page=6",
    "query": {
      "condition": "Carcinoma NOS",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 11974,
    "total_pages": 1198,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+NOS&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+NOS&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T21:27:06.996Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04441138",
      "title": "Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Non-small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2021-02-25",
      "completion_date": "2024-03-31",
      "has_results": true,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-11-18T21:27:06.996Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04441138"
    },
    {
      "nct_id": "NCT02098538",
      "title": "Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenoid Cystic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2014-03",
      "completion_date": "2024-11-07",
      "has_results": true,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-11-18T21:27:06.996Z",
      "location_count": 5,
      "location_summary": "Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rockville Centre",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02098538"
    },
    {
      "nct_id": "NCT00293436",
      "title": "Celecoxib and Erlotinib in Treating Patients With Liver Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "celecoxib",
          "type": "DRUG"
        },
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2005-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-09-17",
      "last_synced_at": "2026-11-18T21:27:06.996Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00293436"
    },
    {
      "nct_id": "NCT01741636",
      "title": "Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stage I Colon Cancer",
        "Stage I Rectal Cancer",
        "Stage IA Non-small Cell Lung Cancer",
        "Stage IB Non-small Cell Lung Cancer",
        "Stage IIA Colon Cancer",
        "Stage IIA Non-small Cell Lung Cancer",
        "Stage IIA Rectal Cancer",
        "Stage IIB Colon Cancer",
        "Stage IIB Non-small Cell Lung Cancer",
        "Stage IIB Rectal Cancer",
        "Stage IIC Colon Cancer",
        "Stage IIC Rectal Cancer",
        "Stage IIIA Colon Cancer",
        "Stage IIIA Non-small Cell Lung Cancer",
        "Stage IIIA Rectal Cancer",
        "Stage IIIB Colon Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IIIB Rectal Cancer",
        "Stage IIIC Colon Cancer",
        "Stage IIIC Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "educational intervention",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2013-01",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-11-18T21:27:06.996Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01741636"
    },
    {
      "nct_id": "NCT05200364",
      "title": "A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Ovarian Carcinoma",
        "Ovary Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "STRO-002",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sutro Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 58,
      "start_date": "2022-03-22",
      "completion_date": "2025-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-11-18T21:27:06.996Z",
      "location_count": 6,
      "location_summary": "Tampa, Florida • Philadelphia, Pennsylvania • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05200364"
    },
    {
      "nct_id": "NCT07226999",
      "title": "Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Small Cell Lung Cancer (SCLC)"
      ],
      "interventions": [
        {
          "name": "PF-08634404",
          "type": "DRUG"
        },
        {
          "name": "Tarlatamab",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 550,
      "start_date": "2025-12-09",
      "completion_date": "2034-03-11",
      "has_results": false,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-18T21:27:06.996Z",
      "location_count": 55,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 41 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07226999"
    },
    {
      "nct_id": "NCT00264433",
      "title": "A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "ADH -1 (Exherin™)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adherex Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-08-06",
      "last_synced_at": "2026-11-18T21:27:06.996Z",
      "location_count": 5,
      "location_summary": "Fort Myers, Florida • Chapel Hill, North Carolina • Durham, North Carolina + 2 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00264433"
    },
    {
      "nct_id": "NCT04158349",
      "title": "Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Appendiceal Cancer",
        "Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "mFOLFIRI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-03-22",
      "completion_date": "2021-05-14",
      "has_results": false,
      "last_update_posted_date": "2021-09-27",
      "last_synced_at": "2026-11-18T21:27:06.996Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04158349"
    },
    {
      "nct_id": "NCT04351555",
      "title": "A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 358,
      "start_date": "2020-12-16",
      "completion_date": "2029-06-13",
      "has_results": true,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-11-18T21:27:06.996Z",
      "location_count": 12,
      "location_summary": "Duarte, California • Irvine, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04351555"
    },
    {
      "nct_id": "NCT02250326",
      "title": "Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "nab-paclitaxel IV",
          "type": "DRUG"
        },
        {
          "name": "CC-486",
          "type": "DRUG"
        },
        {
          "name": "Duravalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2015-01-07",
      "completion_date": "2023-08-17",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-18T21:27:06.996Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • New Britain, Connecticut • Athens, Georgia + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02250326"
    }
  ]
}